Henry Schein, Inc. has secured nationwide exclusive rights to distribute vVARDIS’s Curodont™ Repair Fluoride Plus, a drill‑free, needle‑free early‑cavity treatment, effective January 1, 2026. The agreement expands the company’s prior 2024 exclusivity, which was limited to Dental Service Organizations, to include general dentistry, orthodontics, and pediatric dentistry across the United States.
Curodont™ Repair Fluoride Plus uses peptide‑based remineralization technology to restore enamel without drilling or anesthesia. Since its launch, the product has been adopted by more than 10 % of U.S. dental offices and has treated over 500,000 patients, underscoring its rapid market penetration and the growing demand for minimally invasive care.
By gaining nationwide rights, Henry Schein can now offer the product to every U.S. dental practice, positioning the company to capture a larger share of the high‑margin, non‑invasive cavity‑treatment market. The move complements Henry Schein’s broader strategy of expanding its portfolio of innovative, high‑margin solutions and strengthens its competitive stance against other distributors that lack a unique, needle‑free option.
Henry Schein’s recent financial results reinforce the strategic fit of the expansion. In the third quarter of 2025, the company reported adjusted earnings per share of $1.38, beating analyst expectations of $1.28, and revenue of $3.34 billion, exceeding estimates of $3.28 billion. Management raised its full‑year 2025 adjusted EPS guidance to $4.88–$4.96 and increased its total sales growth forecast to 3–4 % as it continues to drive growth through high‑margin product lines.
"We are pleased to build upon our existing relationship with vVARDIS and bring this innovative, non‑invasive solution to the entire U.S. dental community," said Stanley M. Bergman, Chairman and CEO of Henry Schein. "The expansion reflects our commitment to improving clinical outcomes and practice efficiency while advancing oral health for patients nationwide."
"Our decision to broaden the partnership was driven by the exceptional success we have already achieved, having accessed over 10 % of U.S. dental offices and treated more than 500,000 patients," said Drs. Haley and Goly Abivardi, founders and co‑CEOs of vVARDIS. "Henry Schein’s global reach makes for an ideal partner to make Curodont accessible to the entire U.S. dental community."
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.